Humacyte, Inc. (NASDAQ:HUMA - Get Free Report) shares were up 10% during trading on Wednesday . The stock traded as high as $4.54 and last traded at $4.53. Approximately 2,101,798 shares changed hands during mid-day trading, a decline of 37% from the average daily volume of 3,351,322 shares. The stock had previously closed at $4.12.
Wall Street Analyst Weigh In
HUMA has been the topic of several research analyst reports. D. Boral Capital reissued a "buy" rating and issued a $25.00 target price on shares of Humacyte in a research report on Monday. TD Cowen reiterated a "buy" rating and issued a $10.00 price target on shares of Humacyte in a report on Friday, October 18th. Piper Sandler set a $6.00 price objective on Humacyte and gave the stock a "neutral" rating in a report on Friday, October 18th. BTIG Research reiterated a "buy" rating and issued a $10.00 target price on shares of Humacyte in a report on Friday, October 18th. Finally, Benchmark upped their price target on Humacyte from $15.00 to $17.00 and gave the stock a "buy" rating in a research note on Monday, December 23rd. One analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus price target of $13.71.
Get Our Latest Report on Humacyte
Humacyte Price Performance
The business has a fifty day moving average of $4.60 and a 200 day moving average of $5.66. The stock has a market cap of $555.04 million, a PE ratio of -3.29 and a beta of 1.32.
Insider Buying and Selling at Humacyte
In other news, Director Brady W. Dougan sold 427,459 shares of the business's stock in a transaction dated Tuesday, November 19th. The shares were sold at an average price of $4.34, for a total value of $1,855,172.06. Following the completion of the sale, the director now owns 1,992,253 shares of the company's stock, valued at approximately $8,646,378.02. The trade was a 17.67 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Laura E. Niklason sold 261,369 shares of the stock in a transaction dated Wednesday, November 20th. The stock was sold at an average price of $4.40, for a total transaction of $1,150,023.60. Following the transaction, the chief executive officer now directly owns 1,730,884 shares in the company, valued at $7,615,889.60. The trade was a 13.12 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 1,500,000 shares of company stock valued at $6,606,799 in the last three months. Corporate insiders own 11.20% of the company's stock.
Institutional Investors Weigh In On Humacyte
Several institutional investors and hedge funds have recently made changes to their positions in HUMA. Private Advisor Group LLC boosted its holdings in Humacyte by 1.8% in the third quarter. Private Advisor Group LLC now owns 373,110 shares of the company's stock worth $2,030,000 after purchasing an additional 6,510 shares during the period. SG Americas Securities LLC lifted its position in shares of Humacyte by 22.0% in the 4th quarter. SG Americas Securities LLC now owns 39,143 shares of the company's stock worth $198,000 after buying an additional 7,069 shares during the last quarter. The Manufacturers Life Insurance Company boosted its holdings in shares of Humacyte by 32.5% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 34,919 shares of the company's stock valued at $168,000 after buying an additional 8,557 shares during the period. China Universal Asset Management Co. Ltd. grew its position in shares of Humacyte by 64.1% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 22,955 shares of the company's stock valued at $125,000 after buying an additional 8,965 shares during the last quarter. Finally, Brookstone Capital Management bought a new stake in shares of Humacyte during the 4th quarter valued at about $56,000. 44.71% of the stock is owned by institutional investors and hedge funds.
About Humacyte
(
Get Free Report)
Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Humacyte, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Humacyte wasn't on the list.
While Humacyte currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
